Ionetix Corp / DE /

Overview

• IndustryIn Vitro & In Vivo Diagnostic Substances¹
• HeadquartersLansing, Michigan¹
• Incorporated inDE²
• Business address3130 Sovereign Drive, Lansing, Mi 48911²
• Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company²
• Legal formCorporation

See how the biggest companies compare on our leaderboards

Corporate structure

Ionetix Corp / DE / sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Ionetix Corp / DE /, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerKevin J. Cameron May 13, 2026 to now³
• PresidentKevin J. Cameron May 13, 2026 to now³
• Chief financial officerPhieu Phun Apr 22, 2026 to now⁴

Named in SEC Form D filings

People the company listed in its private-offering notices.

• DirectorGregory Martin named Apr 23, 2026⁹

Former names

• JDEV Acquisition CorpFeb 4, 2026 to Mar 27, 2026²

Timeline

1. May 26, 20268-K Regulation FD disclosure¹⁰
2. May 20, 20268-K Executive or director change; Other events¹¹
3. May 20, 20268-K Financial statements and exhibits¹²
4. May 13, 2026New chief executive Kevin J. Cameron becomes CEO³
5. Apr 16, 20268-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares¹³

Filings

30 filings to the SEC since October 2021: 2 quarterly reports, 4 major events, 15 insider forms, 3 large holders, 1 private raises, 5 other. The latest 20:

1. Aug 12, 202610-Q QUARTERLY REPORT EDGAR
2. Aug 7, 2026S-1 REGISTRATION STATEMENT EDGAR
3. Jul 27, 20263 EDGAR
4. Jul 24, 2026SCHEDULE 13G EDGAR
5. Jul 14, 2026S-8 REGISTRATION STATEMENT EDGAR
6. May 26, 20268-K CURRENT REPORT EDGAR
7. May 20, 20268-K/A AMENDMENT NO. 1 TO FORM 8-K EDGAR
8. May 20, 202610-Q QUARTERLY REPORT EDGAR
9. May 20, 20268-K CURRENT REPORT EDGAR
10. May 13, 20264 EDGAR
11. May 13, 20264/A EDGAR
12. May 13, 20264 EDGAR
13. May 13, 20263 EDGAR
14. Apr 24, 20263 EDGAR
15. Apr 23, 20263 EDGAR
16. Apr 23, 2026D EDGAR
17. Apr 22, 20264 EDGAR
18. Apr 22, 20263 EDGAR
19. Apr 22, 20264 EDGAR
20. Apr 22, 20263 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Eli Lilly and CompanySCHEDULE 13G, 1 filing Jul 24, 2026¹⁴
• Ospraie Real Assets Fund LPSCHEDULE 13G, 1 filing Apr 20, 2026¹⁵
• Shamrock Ionetix LLCSCHEDULE 13D, 1 filing Apr 20, 2026¹⁶

Money raised

Private offerings the company reported to the SEC on Form D.

1. Apr 9, 2026Raised $32.3 million in a private offering of equity Form D: 267 investors so far Form D

SEC filer profile

How Ionetix Corp / DE / is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARIonetix Corp / DE /¹
• CIK0002108121
• Employer ID (EIN)42-2828779¹
• Filer statusNon-accelerated filer<br>smaller reporting company<br>emerging growth company¹
• Incorporated inDelaware¹
• Fiscal year endsDecember 31¹
• Industry code (SIC)2835 In Vitro & In Vivo Diagnostic Substances¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address3130 Sovereign Drive, Lansing, MI 48911¹
• Phone732-241-3073¹
• Shares outstanding106,295,716 as of Jul 31, 2026¹⁷
• On EDGAR sinceFeb 4, 2026¹
• Filings30 in all: 3 (8), 4 (6), 8-K (3), 10-12G/A (2), 10-Q (2), SCHEDULE 13G (2), 10-12G (1), 4/A (1)¹
  All 13 form types

  8-K/A (1), D (1), S-1 (1), S-8 (1), SCHEDULE 13D (1)

• Latest filingsQuarterly report (10-Q) Aug 12, 2026
  Latest 8-K (8-K) May 26, 2026